Sanofi
SEC insider (Form 3/4/5 filer). CIK 0001121404. 10% Owner at Latigo Biotherapeutics, Inc. (LTGO) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Aug 10, 2026. Located in PARIS.
Companies Sanofi has filed insider reports for
- Latigo Biotherapeutics, Inc. (LTGO): 10% Owner
- Attovia Therapeutics, Inc. (ATTO): 10% Owner
Sanofi
CIK: 0001121404
Transaction Breakdown
Open Market Buys (P)1 (25.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)3 (75.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Aug 10, 2026LTGO
Latigo Biotherapeutics, Inc.
ConversionIndirect494.8K shares- - Aug 10, 2026LTGO
Latigo Biotherapeutics, Inc.
ConversionIndirect178K shares- - Aug 6, 2026ATTO
Attovia Therapeutics, Inc.
ConversionIndirect782.9K shares- - Aug 6, 2026ATTO
Attovia Therapeutics, Inc.
PurchaseIndirect300K shares at avg. $17.00$5.1M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 10, 2026 |  LTGO Latigo Biotherapeutics, Inc. | Conversion | 494,800 | - | $0 | Indirect |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Conversion | 177,978 | - | $0 | Indirect |
| Aug 6, 2026 |  ATTO Attovia Therapeutics, Inc. | Conversion | 782,855 | - | $0 | Indirect |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Purchase | 300,000 | $17.00 | $5,100,000 | Indirect |
1-4 of 4 transactions